MedTrace Logo

Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation

NCT07623473 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1800

Last updated 2026-06-03

No results posted yet for this study

Summary

The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule.

Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.

Conditions

  • Lung Cancer (Diagnosis)
  • Nodule, Solitary Pulmonary

Interventions

DIAGNOSTIC_TEST

Blood tests

Standard blood tests, Novel protein tumor markers specifically targeting lung cancer, Epigenetic smoking marker (AHRR methylation), Combined fragmentome, mutational and methylome analysis of cell-free tumor DNA

Sponsors & Collaborators

  • NEYE Foundation

    collaborator UNKNOWN

  • Direktør Michael Hermann Nielsens mindelegat, afd B

    collaborator UNKNOWN

  • Toyota Foundation Denmark

    collaborator UNKNOWN

  • Grosserer L. F. Foghts Fond Denmark

    collaborator UNKNOWN

  • Beckett Foundation

    collaborator OTHER

  • P. A. Messerschmidt & hustrus Fond

    collaborator UNKNOWN

  • Herlev and Gentofte Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-22
Primary Completion
2028-02-01
Completion
2028-02-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07623473 on ClinicalTrials.gov